Segment reporting (Tables)

6 Months Ended

Feb. 29, 2024

Segment Reporting [Abstract]

Reconciliation of Operating Income (Loss) from Segments to Consolidated

The following table reflects results of operations of the Company’s reportable segments (in millions):

	Three months ended				Six months ended
	February 29, 2024		February 28, 2023		February 29, 2024		February 28, 2023
Sales:
U.S. Retail Pharmacy	$	28,861	$	27,577	$	57,805	$	54,781
International	6,022		5,651		11,854		10,840
U.S. Healthcare	2,176		1,634		4,107		2,622
Corporate and Other 1	(6)		—		(6)		—
Walgreens Boots Alliance, Inc.	$	37,052	$	34,862	$	73,760	$	68,244
Adjusted operating income:
U.S. Retail Pharmacy	$	752	$	1,067	$	1,446	$	2,172
International	245		352		387		468
U.S. Healthcare	(34)		(159)		(129)		(311)
Corporate and Other 1	(63)		(44)		(117)		(100)
Walgreens Boots Alliance, Inc.	$	900	$	1,215	$	1,588	$	2,229

1.Includes certain eliminations.

The following table reconciles adjusted operating income to operating (loss) income (in millions):

	Three months ended				Six months ended
	February 29, 2024		February 28, 2023		February 29, 2024		February 28, 2023
Adjusted operating income (Non-GAAP measure)	$	900	$	1,215	$	1,588	$	2,229
Impairment of goodwill, intangibles and long-lived assets	(13,090)		—		(13,090)		—
Acquisition-related amortization	(270)		(247)		(545)		(577)
Acquisition-related costs	(249)		(148)		(412)		(187)
Certain legal and regulatory accruals and settlements	(242)		(427)		(324)		(6,981)
Transformational cost management	(197)		(145)		(306)		(283)
Adjustments to equity earnings in Cencora	(22)		(31)		(72)		(117)
LIFO provision	—		(20)		(48)		(38)
Operating (loss) income (GAAP measure)	$	(13,171)	$	197	$	(13,209)	$	(5,954)